KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBITDA (2016 - 2026)

TherapeuticsMD filings provide 17 years of EBITDA readings, the most recent being -$723000.0 for Q1 2026.

  • On a quarterly basis, EBITDA rose 43.56% to -$723000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.8 million, a 34.56% increase, with the full-year FY2025 number at -$4.4 million, up 28.17% from a year prior.
  • EBITDA hit -$723000.0 in Q1 2026 for TherapeuticsMD, up from -$1.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $112.3 million in Q2 2022 to a low of -$49.0 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$1.1 million (2024), compared with a mean of $5.3 million.
  • Biggest five-year swings in EBITDA: skyrocketed 363.25% in 2022 and later plummeted 138.04% in 2025.
  • TherapeuticsMD's EBITDA stood at $77.7 million in 2022, then tumbled by 101.14% to -$883000.0 in 2023, then increased by 26.16% to -$652000.0 in 2024, then plummeted by 138.04% to -$1.6 million in 2025, then surged by 53.41% to -$723000.0 in 2026.
  • The last three reported values for EBITDA were -$723000.0 (Q1 2026), -$1.6 million (Q4 2025), and -$862000.0 (Q3 2025) per Business Quant data.